Literature DB >> 9733661

Species differences in N-glucuronidation.

S H Chiu1, S W Huskey.   

Abstract

Glucuronidation of amines has been shown to exhibit species differences in vitro and in vivo. Substrates for N-glucuronidation can be classified according to the chemical structures of the resulting glucuronides into two groups: compounds that form non-quaternary N-conjugates, and those that form the quaternary counterparts. For compounds of the former class-such as sulfonamides, arylamines, and alicyclic, cyclic, and heterocyclic amines-species differences appear to be less striking and are of a quantitative nature. No one common laboratory animal species used routinely in metabolism research (e.g. rat, mouse, dog, non-human primate, rabbit, and guinea pig) has been shown to be deficient in N-glucuronidation when all of the substrates studied and reported are taken into consideration. The ability of a species to form N-glucuronides is compound-dependent, although rabbit and guinea pig appear to exhibit the highest capacity for this bioconjugation among preclinical species. For tertiary amines, most notably the tricyclic antidepressant and antihistamine drugs, N-glucuronidation is commonly observed in non-human primates and man. There are examples, however, of quaternary glucuronidation occurring in lower animal species. In exploring species differences in amine conjugation in vivo, it is noted that the apparent absence of N-glucuronides in animal urine may not reflect the inability of that species to form such conjugates, since the N-glucuronides may be excreted in bile. Problems such as degradation or low recoveries commonly encountered in isolation and identification of in vivo metabolites further complicate the interpretation of data. Because of the wide range of pKa values exhibited by various classes of amines, caution also should be exercised for in vitro studies since incubation conditions for N-glucuronidation often are substrate- and species-dependent. Explanations for the species differences observed in N-glucuronidation appear to be emerging as rapid advances are made in the understanding of the glucuronosyltransferases at the molecular level. More information, however, remains to be gathered from the glucuronosyltransferase genes of animal species other than humans before a better understanding of species differences in N-glucuronidation can be achieved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733661

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs).

Authors:  Jin Zhou; Upendra A Argikar; John O Miners
Journal:  Methods Mol Biol       Date:  2021

2.  Characterization of nuciferine metabolism by P450 enzymes and uridine diphosphate glucuronosyltransferases in liver microsomes from humans and animals.

Authors:  Yan-liu LU; Yu-qi HE; Miao WANG; Li ZHANG; Li YANG; Zheng-tao WANG; Guang JI
Journal:  Acta Pharmacol Sin       Date:  2010-12       Impact factor: 6.150

3.  Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation.

Authors:  Brian F Kiesel; Robert A Parise; Jianxia Guo; Donna M Huryn; Paul A Johnston; Raffaele Colombo; Malabika Sen; Jennifer R Grandis; Jan H Beumer; Julie L Eiseman
Journal:  Cancer Chemother Pharmacol       Date:  2016-10-24       Impact factor: 3.333

4.  3,3'-Dimethyl-4,4'-(hexane-1,6-di-yl)bis-[1H-1,2,4-triazol-5(4H)-one].

Authors:  Reşat Ustabaş; Ufuk Coruh; Dilek Unlüer; Tuncer Hökelek; Emel Ermiş
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-09-25

5.  Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha,25-dihydroxyvitamin D3 conjugation.

Authors:  Takanori Hashizume; Yang Xu; Michael A Mohutsky; Jeffrey Alberts; Chad Hadden; Thomas F Kalhorn; Nina Isoherranen; Margaret C Shuhart; Kenneth E Thummel
Journal:  Biochem Pharmacol       Date:  2007-11-22       Impact factor: 5.858

6.  Elucidation of in vitro phase I metabolites of droperidol using UPLC-QTOF MS.

Authors:  Ling Fang; Chao-Xian Lin; Zhi-Wei Zhu; Lin-Shu Zhao; Shu-Yao Zhang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-03-05       Impact factor: 2.441

7.  Ethyl 4-(3-ethyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-4-yl)benzoate.

Authors:  Yasemin Unver; Yavuz Köysal; Hasan Tanak; Dilek Unlüer; Samil Işık
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-05-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.